Department of Hematology-Oncology, National University Hospital, National University Health System, Singapore, Singapore.
J Palliat Med. 2010 Aug;13(8):945-8. doi: 10.1089/jpm.2010.0084.
The use of chemotherapy at the end of life is increasing. We characterized the use of targeted therapies in relation to the end of life in non-small cell lung cancer (NSCLC) patients who died in our institution. The frequency of systemic anticancer therapy usage at the end of life was consistent with that reported in other recent studies. The use of targeted therapies, especially epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), was strikingly more common than that of conventional chemotherapy. Targeted therapy was frequently initiated within the last 3 months of life. Targeted agents were also used in sequence, in combination, and in investigational protocols. We conclude that targeted agents, in particular EGFR TKIs, are now the drugs of choice in the systemic treatment of NSCLC at the end of life.
在生命末期使用化疗的情况正在增加。我们描述了在我院死亡的非小细胞肺癌（NSCLC）患者生命末期使用靶向治疗的情况。生命末期使用系统抗癌治疗的频率与其他最近研究报道的一致。靶向治疗的使用，特别是表皮生长因子受体（EGFR）酪氨酸激酶抑制剂（TKI），比传统化疗更为常见。靶向治疗通常在生命的最后 3 个月内开始。靶向药物也被用于序贯治疗、联合治疗和临床试验方案。我们得出结论，靶向药物，特别是 EGFR TKI，现在是 NSCLC 生命末期全身治疗的首选药物。
